EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cardiometabolic screening, elevated results and clinical follow-up actions in Māori and non-Māori with psychosis in Canterbury, Aotearoa New Zealand

Nathan Monk iD, Emily Barrett iD, Julie Fitzjohn, Mau Te Rangimarie Clark iD, Melissa Kerdemelidis, Ruth Cunningham iD, Andre McLachlan, Waikaremoana Waitoki iD, Richard Porter iD, Cameron Lacey

Australian & New Zealand Journal of Psychiatry · 2026

DOI: 10.1177/00048674261461979 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Australian & New Zealand Journal of Psychiatry, 2026. Verfasst von Nathan Monk und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychological Medicine, University of Otago, Christchurch, New Zealand. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Mass Screening, Psychotic Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Research Council of New Zealand.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Estimate and compare rates of cardiometabolic blood screening, elevated results and clinical follow-up actions for Māori and non-Māori mental health service users with psychosis in Canterbury, Aotearoa New Zealand.

Methods

A retrospective cohort study ( N = 3840) with dynamic entry was conducted with people aged 18–64 years with a psychosis diagnosis in Canterbury Specialist Mental Health Service (1 August 2012 to 31 December 2019). Linked administrative data captured lipid and HbA1c screening within 1 year of study entry, elevated results (triglycerides > 2.2 mmol/L; total cholesterol:high-density lipoprotein cholesterol > 5; HbA1c > 40 mmol/mol) from individual study entry to 31 December 2023, and clinical actions (repeat test; statin/metformin dispensing) within 1 year following an elevated result.

Results

887/3840 (23%) of Canterbury Specialist Mental Health Service users with psychosis were Māori. First-year screening rates were modest (31–44%), similar by ethnicity and broadly higher among clozapine/olanzapine users. Māori had higher odds of both elevated lipids and HbA1c. About one-third of elevated results were followed up with re-testing within 1 year. Rates of follow-up testing and medication dispensing were broadly similar for Māori and non-Māori, except Māori were more likely to receive repeat HbA1c testing after an elevated result (odds ratio = 1.71 [1.16, 2.50]).

Conclusions

Findings highlight large gaps in cardiometabolic screening and follow-up actions among Māori and non-Māori Specialist Mental Health Service users with psychosis. Māori presented with psychosis 4 years younger, had significantly higher rates of elevated cardiometabolic risk markers and were more likely to receive HbA1c re-testing following an elevated result.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesMass ScreeningPsychotic DisordersAdolescentAdultFemaleHumansMaleMiddle AgedYoung AdultFollow-Up StudiesGlycated HemoglobinMaori PeopleNew ZealandRetrospective Studies

Stichwörter der Autor:innen

HbA1cMāori healthPsychosisantipsychotic medicationcardiometabolic riskhealth inequitylipids

Substanzen

Glycated Hemoglobin

Autor:innen und Institutionen

  • Department of Psychological Medicine, University of Otago, Christchurch, New Zealand.
  • Department of Māori/Indigenous Health Innovation, University of Otago, Christchurch, New Zealand.
  • Specialist Mental Health Service, Health New Zealand - Canterbury (Te Whatu Ora - Waitaha), Christchurch, New Zealand.
  • Population Health Gain, Service Improvement and Innovation, Health New Zealand - Canterbury (Te Whatu Ora - Waitaha), Christchurch, New Zealand.
  • Department of Public Health, University of Otago, Wellington, New Zealand.
  • Centre for Health and Social Practice, Waikato Institute of Technology, Hamilton, New Zealand.

ORCID-Profile: Nathan Monk, Emily Barrett, Mau Te Rangimarie Clark, Ruth Cunningham, Waikaremoana Waitoki, Richard Porter

Förderung

  • Health Research Council of New Zealand

Zitieren

APA

Monk, N., Barrett, E., Fitzjohn, J., Clark, M. T. R., Kerdemelidis, M., Cunningham, R., McLachlan, A., Waitoki, W., Porter, R., & Lacey, C. (2026). Cardiometabolic screening, elevated results and clinical follow-up actions in Māori and non-Māori with psychosis in Canterbury, Aotearoa New Zealand. Australian & New Zealand Journal of Psychiatry. https://doi.org/10.1177/00048674261461979

Vancouver

Monk N, Barrett E, Fitzjohn J, Clark MTR, Kerdemelidis M, Cunningham R, et al. Cardiometabolic screening, elevated results and clinical follow-up actions in Māori and non-Māori with psychosis in Canterbury, Aotearoa New Zealand. Australian & New Zealand Journal of Psychiatry. 2026. doi:10.1177/00048674261461979

BibTeX
@article{Monk2026,
  author = {Monk, Nathan and Barrett, Emily and Fitzjohn, Julie and Clark, Mau Te Rangimarie and Kerdemelidis, Melissa and Cunningham, Ruth and McLachlan, Andre and Waitoki, Waikaremoana and Porter, Richard and Lacey, Cameron},
  title = {Cardiometabolic screening, elevated results and clinical follow-up actions in Māori and non-Māori with psychosis in Canterbury, Aotearoa New Zealand},
  journal = {Australian & New Zealand Journal of Psychiatry},
  year = {2026},
  doi = {10.1177/00048674261461979}
}
Kostenlos starten →